Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC1118 in Advanced Solid Cancers
NCT02352571Phase 1Unknown
- Sponsor
- GC Biopharma
- Start
- Jan 2015
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC1118 in solid tumor, gastric cancer (GC) and colorectal cancer (CRC), sponsored by GC Biopharma. Primary endpoints: Occurrence of Dose Limiting Toxicity at 6 months, Frequency of Adverse Events at 6 months and 1 more. Status: unknown.
02
Drugs
GC1118
03
Conditions
solid tumorgastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02352571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02352571.